Agouron Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Agouron Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials none currently recruiting 9 completed early-phase tilt top decile by trial count

Agouron Pharmaceuticals: 10 sponsored US clinical trials, none currently recruiting.

Agouron Pharmaceuticals sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cytomegalovirus Retinitis, with 1 trials.

Top-decile sponsor footprint

Agouron Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

C 65/100

9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Indexed trials (enrollment closed)

10 total, page 1 of 1

TERMINATED NA

Safety and Effectiveness of 3 Anti-HIV Treatments in Patients Who Have Failed Previous Treatments Containing Nelfinavir

NCT00006326
COMPLETED Phase 2

A Study of Capravirine Plus VIRACEPT Plus Two Nucleoside Reverse Transcriptase Inhibitors in HIV-Infected Patients Who Failed Previous Anti-HIV Treatments

NCT00006211
COMPLETED Phase 2

Combination Treatment Using Capravirine (AG1549), Nelfinavir, and Two Nucleoside Reverse Transcriptase Inhibitors in HIV Patients Who Failed Initial Combination Therapy

NCT00004985
COMPLETED Phase 2

A Study of Viracept in AIDS Patients With Cytomegalovirus Retinitis

NCT00002169
COMPLETED Phase 2

A Pilot, Open-Label, Phase II, Randomized Study to Determine the Effects of Viracept on the Outcome of Cutaneous and Mucosal KS in AIDS Patients With CD4 <= 500 Cells/mm3

NCT00002185
COMPLETED NA

Viracept Expanded Access Program

NCT00002165
COMPLETED Phase 2

A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC)

NCT00002170
COMPLETED Phase 1

Phase I Study of Safety, Tolerability, and Pharmacokinetics of Viracept in HIV-1 Infected Children and Exposed Infants

NCT00002164
COMPLETED Phase 2

Safety and Effectiveness of Treating HIV-Positive Patients With an HIV Vaccine (Remune)

NCT00005001
COMPLETED Phase 2

A Study of Viracept in HIV-Positive Women

NCT00002171

Phase Distribution

PhaseTrial count
Phase 1 1
Phase 2 7

Therapeutic Areas

Cytomegalovirus Retinitis 1
HIV Infections 1

How the Agouron Pharmaceuticals early-phase archive is shaped

10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).

Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).

Top condition: Cytomegalovirus Retinitis (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Agouron Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Agouron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Agouron PharmaceuticalsAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAimmune Therapeutics10xBio22nd Century Group23andMe3-C Institute for Social Development
Agouron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Agouron Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Agouron Pharmaceuticals page

10 registered trials is a research-attention snapshot, not an endorsement of Agouron Pharmaceuticals or any single study.

  • None of Agouron Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Cytomegalovirus Retinitis is the condition Agouron Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cytomegalovirus Retinitis trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Agouron Pharmaceuticals pipeline card: 10 registered trials from official public datasets.Report a data error.